{"id":"W2885455637","doi":"","title":"Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial","year":2017,"lang":"en","type":"article","venue":"Data Archiving and Networked Services (DANS)","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Crizotinib; Medicine; Refractory (planetary science); Randomized controlled trial; Oncology; Internal medicine; Lung cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004804824,0.0002799233,0.0007780572,0.00006779867,0.000451964,0.0002782505,0.0004151629,0.00006905729,0.0000413201],"category_scores_gemma":[0.00004485669,0.0002118949,0.00006635486,0.000045661,0.0002295089,0.000473142,0.0004091708,0.0002791208,0.000002171453],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005872994,"about_ca_system_score_gemma":0.0001970339,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008565933,"about_ca_topic_score_gemma":0.003403512,"domain_scores_codex":[0.9980252,0.0002135147,0.0004676985,0.000643784,0.0002317794,0.0004179768],"domain_scores_gemma":[0.9978678,0.0005440714,0.0003000317,0.0009960441,0.0000206787,0.0002713502],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6534776,0.003089547,0.1082826,0.0006889689,0.003575325,0.000597697,0.02688775,0.0001123745,0.001569935,0.0004267581,0.001134822,0.2001566],"study_design_scores_gemma":[0.7545472,0.0003624755,0.1213294,0.0009791558,0.001109319,0.00001687694,0.0008487061,0.117922,0.00001663755,0.0003816283,0.002166093,0.0003204973],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932734,0.0009507443,0.0003862183,0.0005034147,0.0004415992,0.001243235,0.001062304,0.00004677475,0.002092291],"genre_scores_gemma":[0.9899513,0.0009633681,0.001985901,0.0002446254,0.000658085,0.00007880271,0.005999926,0.00002986901,0.00008808768],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1998361,"threshold_uncertainty_score":0.9980361,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02737241111487777,"score_gpt":0.3839136145247545,"score_spread":0.3565412034098768,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}